



Physicians' CME Credit Tracking Tool

Download and save this tool, then use it to track CME sessions as you view them.



When you're ready to claim credit, go to the eLearning portal: education.IASLC.org/WCLC2021-credit-claim



Follow the instructions to claim your credit and receive your CME Certificate.

The CME credit claim process can only be completed once.
The credit claim portal opens September 14 and closes December 17, 2021.

EARLY RELEASE CME CONTENT (Pre-release)

Check	Session #	Session Title	Credit
	ES01 (Pre)	Proactive Tobacco and Cancer Control	1.0
	ES02 (Pre)	Multidisciplinary Collaboration in the Treatment of Oligometastatic Disease	1.0
	ES03 (Pre)	Optimizing Survival with Multidisciplinary Collaboration	1.0
	ES04 (Pre)	Antibody-Drug Conjugates: Current Status and Future Perspectives	1.0
	ES05 (Pre)	A New Era of Treatment and Diagnosis for Mesothelioma and Thymoma	1.0
	ES06 (Pre)	Immuno-Biology and Novel Immunotherapeutics in Lung Cancer	1.0
	ES07 (Pre)	Grief and Loss in Palliative Care	1.0
	ES08 (Pre)	What has COVID-19 Taught Us About Improving Management of Treatment for Patients ...	1.0
	ES09 (Pre)	Pathology Assessment & Biomarker Testing: Implications of/for Adjuvant & Neoadjuvant Therapy	1.0
	ES10 (Pre)	Optimizing Clinical Outcomes in Lung Cancer: The Value of Tobacco Cessation	1.0
	ES11 (Pre)	Small Cell Lung Cancer: Recent Preclinical Advances and Emerging Approaches to Therapy	1.0
	ES12 (Pre)	A Precision Approach to Stage III Non-small Cell Lung Cancer	1.0
	ES13 (Pre)	Ethics, Costs, and Regulation of Lung Cancer	1.0
	ES14 (Pre)	Liquid Biopsy and Other Non-invasive Diagnostic Modalities	1.0
	ES15 (Pre)	The Impact of Implicit Biases in Oncology Care	1.0
	ES16 (Pre)	Evolving Science for Stage I Non-small Cell Lung Cancer	1.0
	ES17 (Pre)	TNM Staging and Drug-Related Pneumonitis	1.0
	ES18 (Pre)	Tumor Biology and Systems Biology - Basic and Translational Science	1.0
	ES19 (Pre)	Lung Cancer on a Global Scale: Challenges and Innovations	1.0
	ES20 (Pre)	Caveats, Challenges, Controversies in Immunotherapy of Lung Cancer: Phase II & Phase III Trials	1.0
	ES21 (Pre)	Screening and Early Detection in Lung Cancer	1.0



2021 World Conference on Lung Cancer

SEPTEMBER 8-14, 2021 | WORLDWIDE VIRTUAL EVENT



CME Credit & Attendance Certificates

DAY 1 CME CONTENT

Check	Session #	Session Title	Credit
	PL01	Opening Plenary 1 - Access and Disparities	1.0
	MA01	Multimodality Management of Advanced Lung Cancer	1.0
	MA02	RET and Novel Combinations of Osimertinib	1.0
	MA03	Biomarkers for Immunotherapy: Are All Relevant?	1.0
	MA04	Current Status and Future Prospects of Pleural Mesothelioma and Thymoma	1.0
	OA01	The Impact of COVID-19 on Patients with Lung Cancer	1.0
	OA02	Contemporary Approaches to Supportive Care	1.0
	OA03	Novel Approaches to Cessation in Cancer Care	1.0
	OA04	Improving Thoracic Oncology Patient Outcomes	1.0
	OA05	Palliative Care Service Models	1.0

DAY 2 CME CONTENT

Check	Session #	Session Title	Credit
	PL02	Plenary 2 - Presidential Symposium	1.5
	PL02A	Plenary 2A - Presidential Symposium (Re-Broadcast)	1.5
	MA05	Using Real World & Patient Reported Data to Identify Gaps & Needs for People with Lung Cancer ...	1.0
	MA06	Differentiating Outcomes and Impact in Unresectable Non-small Cell Lung Cancer	1.0
	MA07	Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early-Stage NSCLC	1.0
	MA08	Driver Mutations and Immune Profiles in Early-Stage Non-small Cell Lung Cancer	1.0
	OA06	Prognosis and Staging	1.0
	OA07	What's on the Horizon for Small Cell Lung Cancer?	1.0
	OA08	Moving Beyond New Drugs: What Else Matters?	1.0
	OA09	Expanding Immunotherapy Options for Non-small Cell Lung Cancers	1.0
	OA10	Improving Care for People with Lung Cancer: Biomarker Testing Access, Psychosocial Distress ...	1.0
	OA11	Early-Stage Non-small Cell Lung Cancer	1.0
	OA12	Understanding and Augmenting Responses to Immunotherapy for Thoracic Malignancies	1.0

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates this Other activity (blended live, simulative, and on-demand materials) for a maximum of 77 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



2021 World Conference on Lung Cancer

SEPTEMBER 8-14, 2021 | WORLDWIDE VIRTUAL EVENT



CME Credit & Attendance Certificates

DAY 3 CME CONTENT

Check	Session #	Session Title	Credit
	ES01	Proactive Tobacco and Cancer Control	0.5
	ES02	Multidisciplinary Collaboration in the Treatment of Oligometastatic Disease	0.5
	ES03	Optimizing Survival with Multidisciplinary Collaboration	0.5
	ES04	Antibody-Drug Conjugates: Current Status and Future Perspectives	0.5
	ES05	A New Era of Treatment and Diagnosis for Mesothelioma and Thymoma	0.5
	ES06	Immuno-Biology and Novel Immunotherapeutics in Lung Cancer	0.5
	ES07	Grief and Loss in Palliative Care	0.5
	ES08	What has COVID-19 Taught Us About Improving Management of Treatment for Patients ...	0.5
	ES09	Pathology Assessment & Biomarker Testing: Implications of/for Adjuvant & Neoadjuvant Therapy	0.5
	ES10	Optimizing Clinical Outcomes in Lung Cancer: The Value of Tobacco Cessation	0.5
	ES11	Small Cell Lung Cancer: Recent Preclinical Advances and Emerging Approaches to Therapy	0.5

DAY 4 CME CONTENT

Check	Session #	Session Title	Credit
	WS03	Workshop: Women in Thoracic Oncology	1.5

DAY 5 CME CONTENT

Check	Session #	Session Title	Credit
	PL03	Plenary 3 - Screening: The Global Landscape, Progress, and Future Directions	1.0
	MA09	Predictive Markers for Immunotherapy	1.0
	MA10	Screening and Early Detection: An Overview	1.0
	MA11	New Biological Insights for Targeted Therapies	1.0
	MA12	The Impact of COVID-10 on How We Treat Thoracic Cancer Now, and in the Future	1.0
	OA13	Topics of Pleural Mesothelioma	1.0
	OA14	Global Disparities in Lung Cancer Care	1.0
	OA15	Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation	1.0
	OA16	Clinical Impact of Liquid Biopsy for Patients with Non-small Cell Lung Cancer	1.0
	OA17	Multidisciplinary Care of Thoracic Oncology Patients During COVID-19 Pandemic	1.0



DAY 6 CME CONTENT

Check	Session #	Session Title	Credit
	MA13	Building on the Past: What Will Be the Next Immunotherapy Combination?	1.0
	MA14	Pathologic Patterns, Genomic Alterations & Targeted Therapies in Non-small Cell Lung Cancer	1.0
	MA15	Real World Factors Affecting Lung Cancer Outcomes	1.0
	MA16	Small Cell Lung Cancer: New Targets, Biomarkers, and Systemic Therapies	1.0
	MA17	Diagnostics and Pulmonology	1.0
	OA18	Real World Data in a Modern World	1.0
	OA19	Screening and Early Detection: State of the Art	1.0
	OA20	Exploring Treatment Modalities & Tools in Locally Advanced Non-small Cell Lung Cancer	1.0

DAY 7 CME CONTENT

Check	Session #	Session Title	Credit
	PL04	Plenary 4 - Stigma as Risk Factor: Why You Should Care	1.0
	PL05	Closing Plenary 5 - Immunotherapy and Beyond: Future Directions	1.0
	ES12	A Precision Approach to Stage III Non-small Cell Lung Cancer	0.5
	ES13	Ethics, Costs, and Regulation of Lung Cancer	0.5
	ES14	Liquid Biopsy and Other Non-invasive Diagnostic Modalities	0.5
	ES15	The Impact of Implicit Biases in Oncology Care	0.5
	ES16	Evolving Science for Stage I Non-small Cell Lung Cancer	0.5
	ES17	TNM Staging and Drug-Related Pneumonitis	0.5
	ES18	Tumor Biology and Systems Biology - Basic and Translational Science	0.5
	ES19	Lung Cancer on a Global Scale: Challenges and Innovations	0.5
	ES20	Caveats, Challenges & Controversies in Immunotherapy of Lung Cancer: Phase II & Phase III Trials	0.5
	ES21	Screening and Early Detection in Lung Cancer (0.5 credit)	0.5

The CME credit claim process can only be completed once.

The credit claim portal opens September 14 and closes December 17, 2021.

If you have questions about this tracking tool or your CME Credit,
please contact IASLC Education staff at education@iaslc.org.